001041341 001__ 1041341
001041341 005__ 20260123203310.0
001041341 0247_ $$2doi$$a10.1016/j.ebiom.2025.105648
001041341 0247_ $$2datacite_doi$$a10.34734/FZJ-2025-02231
001041341 037__ $$aFZJ-2025-02231
001041341 082__ $$a610
001041341 1001_ $$0P:(DE-Juel1)156374$$aKovermann, Peter$$b0
001041341 245__ $$aThe severity of SLC1A2-associated neurodevelopmental disorders correlates with transporter dysfunction
001041341 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
001041341 3367_ $$2DRIVER$$aarticle
001041341 3367_ $$2DataCite$$aOutput Types/Journal article
001041341 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769161785_19119
001041341 3367_ $$2BibTeX$$aARTICLE
001041341 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001041341 3367_ $$00$$2EndNote$$aJournal Article
001041341 500__ $$aWe thank the patients and families who participated in the collection of clinical data for this project and for enrolling in our research studies. Drs. M. Hediger (Universität Bern, Switzerland) and S.G. Amara (National Institutes of Health, Bethesda, MD) are thanked for their generous gifts of EAAT2 cDNAs. AAJ was supported by the Lundbeck Foundation, and ChF was supported by the German Ministry of Education and Research (BMBF 01GM2210D, E-RARE network, Treat-ION).
001041341 520__ $$aL-Glutamate (L-Glu) is the major excitatory neurotransmitter in the human brain, where it is involved in or contributes to essentially all central functions. Glutamatergic hyper- or hypofunction have been linked to a range of neurological, cognitive, and psychiatric disorders, and thus glutamatergic receptors, transporters and enzymes constitute promising therapeutic targets.1, 2, 3Following its release from presynaptic terminals, L-Glu is quickly taken up into glia and neurons by five excitatory amino acid transporters (EAAT1-5) from solute carrier 1 (SLC1) family of Na+-dependent transporters.4, 5, 6 The EAAT functions as a homotrimeric assembly, with each monomer comprising intracellular amino- and carboxy-termini, eight transmembrane domains (TM1-8) and two hairpin structures (HP1-2) with interconnecting extra- and intracellular loops.5,7,8 The transport domain (TM3,6–8, HP1-2) in the monomer mediates stoichiometrically coupled L-Glu transport via an elevator mechanism driven by co-transport of three Na+ and one H+ and counter-transport of one K+, while the trimerization domain (TM1-2,4–5) is anchored to the plasma membrane making inter-monomeric contacts.5,7, 8, 9, 10 EAATs also act as anion channels that open and close during transitions along the L-Glu transport cycle via brief gap openings between the transport and trimerization domains.11, 12, 13, 14, 15Variants in SLC1A1-3 and SLC1A6-7 encoding for the five EAATs have been linked with various neurological and neuropsychiatric disorders.16,17 For example, we and others have found missense SLC1A3 variants associated with episodic ataxia 6 to change EAAT1 anion channel conduction.13,18, 19, 20, 21 EAAT2, the predominant glial and presynaptic EAAT subtype, is abundantly expressed throughout the brain, where it mediates ∼90% of total central L-Glu uptake,4,22,23 which makes SLC1A2 variants of potential importance for a range of central nervous system (CNS) disorders.24, 25, 26 Recently, three missense SLC1A2 variants associated with developmental and epileptic encephalopathies (DEEs)27, 28, 29, 30 were reported to significantly alter EAAT2 anion channel function.24 However, the SLC1A2-related phenotype remains ill-defined, and genotype-phenotype correlations have not been reported.With the present study we aim to provide the first genotype-phenotype correlation analysis for SLC1A2, to elucidate the molecular phenotypic basis for SLC1A2-associated neurodevelopmental disorders, and to provide the basis for future predictions of disease progression and severity of these. We present a cohort of 18 individuals with 13 presumed pathogenic SLC1A2 variants presenting with neurodevelopmental disorders and DEEs. We delineate the effects induced by nine novel missense variants on EAAT2 expression and function via heterologous expression of wild-type (WT) and mutant transporters in mammalian cell lines, and we deep-phenotype the neurodevelopmental disorders and epileptology associated with SLC1A2 variants.
001041341 536__ $$0G:(DE-HGF)POF4-5241$$a5241 - Molecular Information Processing in Cellular Systems (POF4-524)$$cPOF4-524$$fPOF IV$$x0
001041341 536__ $$0G:(BMBF)01GM1907C$$aTreat-ION - Neue Therapien für neurologische Ionenkanal- und Transporterstörungen - Teilprojekt 6 Zelluläre Pathophysiologie (01GM1907C)$$c01GM1907C$$x1
001041341 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001041341 7001_ $$0P:(DE-HGF)0$$aBayat, Allan$$b1
001041341 7001_ $$0P:(DE-HGF)0$$aFenger, Christina D.$$b2
001041341 7001_ $$0P:(DE-HGF)0$$aLeeuwen, Lisette$$b3
001041341 7001_ $$0P:(DE-HGF)0$$aBorovikov, Artem$$b4
001041341 7001_ $$0P:(DE-HGF)0$$aSharkov, Artem$$b5
001041341 7001_ $$0P:(DE-HGF)0$$aLevrat, Virginie$$b6
001041341 7001_ $$0P:(DE-HGF)0$$aLesca, Gaetan$$b7
001041341 7001_ $$0P:(DE-HGF)0$$aPerrin, Laurence$$b8
001041341 7001_ $$0P:(DE-HGF)0$$aLevy, Jonathan$$b9
001041341 7001_ $$0P:(DE-Juel1)136837$$aFahlke, Christoph$$b10
001041341 7001_ $$0P:(DE-HGF)0$$aMøller, Rikke S.$$b11
001041341 7001_ $$0P:(DE-HGF)0$$aJensen, Anders A.$$b12$$eCorresponding author
001041341 773__ $$0PERI:(DE-600)2799017-5$$a10.1016/j.ebiom.2025.105648$$gVol. 114, p. 105648 -$$p105648 -$$tEBioMedicine$$v114$$x2352-3964$$y2025
001041341 8564_ $$uhttps://juser.fz-juelich.de/record/1041341/files/E_Bio_Medicine_Kovermann_Fahlke_04_2025.pdf$$yOpenAccess
001041341 909CO $$ooai:juser.fz-juelich.de:1041341$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
001041341 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156374$$aForschungszentrum Jülich$$b0$$kFZJ
001041341 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)136837$$aForschungszentrum Jülich$$b10$$kFZJ
001041341 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5241$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
001041341 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
001041341 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
001041341 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
001041341 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEBIOMEDICINE : 2022$$d2025-01-07
001041341 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEBIOMEDICINE : 2022$$d2025-01-07
001041341 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T08:51:17Z
001041341 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T08:51:17Z
001041341 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
001041341 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
001041341 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
001041341 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001041341 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T08:51:17Z
001041341 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
001041341 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
001041341 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
001041341 920__ $$lyes
001041341 9201_ $$0I:(DE-Juel1)IBI-1-20200312$$kIBI-1$$lMolekular- und Zellphysiologie$$x0
001041341 980__ $$ajournal
001041341 980__ $$aVDB
001041341 980__ $$aUNRESTRICTED
001041341 980__ $$aI:(DE-Juel1)IBI-1-20200312
001041341 9801_ $$aFullTexts